PDE9A: A Promising Drug Target and Biomarker for Parkinson's disease

Target Name: PDE9A

NCBI ID: G5152

PDE9A

Other Name(s): High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (isoform d) | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (isoform a) | High affinity cGMP-specific 3',5'-cyclic phospho

PDE9A: A Promising Drug Target and Biomarker for Parkinson's disease

Introduction

Parkinson's disease is a neurodegenerative disease characterized by the degeneration of dopaminergic neurons in the substantia nigrostriatum, which seriously affects patients' quality of life and health status. The pathogenesis of Parkinson's disease is not fully understood, but studies have shown that the main pathogenesis of Parkinson's disease is the degeneration of dopaminergic neurons, which includes the overactivation and death of dopaminergic neurons and the imbalance of survivor neurons. Therefore, the therapeutic target for Parkinson's disease is usually dopaminergic neurons, especially nigrostriatal dopaminergic neurons.

PDE9A: a potential drug target

PDE9A is a protein that belongs to the Ca2+ channel and has multiple biological functions in cells. Studies have found that PDE9A is upregulated in the mesolimbic system (striatum-striatal system) of patients with Parkinson's disease. In addition, PDE9A accumulates in the brains of Parkinson's disease patients, and its expression level is positively correlated with disease severity. These findings suggest that PDE9A may be a potential drug target for the treatment of Parkinson's disease.

Mechanism of action of PDE9A

PDE9A is a calcium channel with multiple biological functions in cells. The main function of PDE9A is to regulate Ca2+ ion influx, thereby affecting neuronal excitability. In patients with Parkinson's disease, overactivation of PDE9A may lead to overactivation of neurons, increase neuronal damage, and aggravate the disease. By inhibiting the action of PDE9A, neuronal damage can be reduced and symptoms of Parkinson's disease improved.

Drug targets for PDE9A

PDE9A, as a calcium channel, has multiple drug targets. First, PDE9A can be inhibited by drugs to inhibit calcium ion influx, thereby reducing neuronal excitability. Secondly, PDE9A can regulate the homeostasis of Ca2+ ions and affect the binding of Ca2+ ions to receptors on the neuronal membrane, thereby affecting neuronal signal transmission. In addition, PDE9A can also regulate voltage-dependent calcium ion channels on neuronal membranes and affect neuronal action potential formation.

Biological functions of PDE9A

PDE9A has multiple biological functions in the pathogenesis of Parkinson's disease. First, overactivation of PDE9A may lead to overactivation of neurons, increase neuronal damage, and aggravate the condition. Secondly, excessive activation of PDE9A may affect neuronal apoptosis, aggravate neuronal death and aggravate the condition. In addition, excessive activation of PDE9A may affect neuronal synaptic plasticity, reduce neuronal adaptability, and aggravate the disease.

Clinical applications of PDE9A

PDE9A has attracted the attention of many researchers as a potential drug target. Currently, some research teams are exploring the possibility of PDE9A as a therapeutic target for Parkinson's disease. If the findings confirm that PDE9A is a potential drug target, treatment options for Parkinson's disease may become more effective and beneficial.

Protein Name: Phosphodiesterase 9A

Functions: Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP (PubMed:9624146, PubMed:18757755, PubMed:21483814). Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart (PubMed:25799991). Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein (Probable). In brain, involved in cognitive function, such as learning and long-term memory (By similarity)

The "PDE9A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE9A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets